X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (36) 36
female (30) 30
male (30) 30
oncology (29) 29
index medicus (28) 28
aged (25) 25
middle aged (25) 25
adult (19) 19
aged, 80 and over (16) 16
sulfonamides - administration & dosage (16) 16
sulfonamides - adverse effects (14) 14
leukemia, lymphocytic, chronic, b-cell - drug therapy (13) 13
treatment outcome (13) 13
administration, oral (12) 12
cancer (12) 12
leukemia (12) 12
antineoplastic agents - adverse effects (11) 11
bridged bicyclo compounds, heterocyclic - administration & dosage (11) 11
analysis (10) 10
chemotherapy (10) 10
antineoplastic agents - administration & dosage (9) 9
antineoplastic agents - pharmacokinetics (9) 9
dose-response relationship, drug (9) 9
lymphomas (9) 9
proto-oncogene proteins c-bcl-2 - antagonists & inhibitors (9) 9
sulfonamides - pharmacokinetics (9) 9
expression (8) 8
human necessities (8) 8
hygiene (8) 8
medical or veterinary science (8) 8
preparations for medical, dental, or toilet purposes (8) 8
rituximab (8) 8
aniline compounds - adverse effects (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
apoptosis (7) 7
bridged bicyclo compounds, heterocyclic - adverse effects (7) 7
disease-free survival (7) 7
hematology (7) 7
neoplasms - drug therapy (7) 7
open-label (7) 7
pharmacokinetics (7) 7
pharmacology & pharmacy (7) 7
specific therapeutic activity of chemical compounds ormedicinal preparations (7) 7
venetoclax (7) 7
abridged index medicus (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic agents - therapeutic use (6) 6
article (6) 6
bcl-2 (6) 6
care and treatment (6) 6
chemistry (6) 6
cohort studies (6) 6
drug administration schedule (6) 6
heterocyclic compounds (6) 6
metallurgy (6) 6
organic chemistry (6) 6
proteins (6) 6
recurrence (6) 6
therapy (6) 6
time factors (6) 6
aniline compounds - administration & dosage (5) 5
aniline compounds - pharmacokinetics (5) 5
animals (5) 5
area under curve (5) 5
chromosome deletion (5) 5
chronic lymphatic leukemia (5) 5
chronic lymphocytic leukemia (5) 5
chronic lymphocytic-leukemia (5) 5
clinical trials (5) 5
cll (5) 5
fludarabine (5) 5
inhibitor (5) 5
leukemia, lymphocytic, chronic, b-cell - mortality (5) 5
maximum tolerated dose (5) 5
patients (5) 5
research (5) 5
resistance (5) 5
tumors (5) 5
abt-199 (4) 4
acyclic, carbocyclic or heterocyclic compounds containingelements other than carbon, hydrogen, halogen, oxygen, nitrogen,sulfur, selenium or tellurium (4) 4
bridged bicyclo compounds, heterocyclic - pharmacokinetics (4) 4
cancer therapies (4) 4
clonal deletion (4) 4
cyclophosphamide (4) 4
disease progression (4) 4
diseases (4) 4
drug dosages (4) 4
drug resistance, neoplasm (4) 4
hematology, oncology and palliative medicine (4) 4
ibrutinib (4) 4
leukemia, lymphocytic, chronic, b-cell - pathology (4) 4
lymphatic leukemia (4) 4
neutropenia (4) 4
pharmacology/toxicology (4) 4
rabbits (4) 4
relapse (4) 4
ryanodine - analogs & derivatives (4) 4
studies (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
DOSE-ESCALATION | APOPTOSIS | MEDICINE, GENERAL & INTERNAL | CLL | INTERNATIONAL WORKSHOP | CYCLOPHOSPHAMIDE | RITUXIMAB | IBRUTINIB | INHIBITOR | PHASE-I | FLUDARABINE | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Lymphomas | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 04/2013, Volume 73, Issue 8 Supplement, pp. SY24-02 - SY24-02
Journal Article
Nature Medicine, ISSN 1078-8956, 02/2013, Volume 19, Issue 2, pp. 202 - 208
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 2, pp. 230 - 240
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 12, pp. 1149 - 1159
Journal Article
The AAPS Journal, ISSN 1550-7416, 9/2016, Volume 18, Issue 5, pp. 1192 - 1202
Venetoclax (ABT-199/GDC-0199) is a selective, potent, first-in-class BCL-2 inhibitor that restores apoptosis in cancer cells and has demonstrated clinical... 
Biochemistry, general | Biotechnology | Biomedicine | food effect | Pharmacy | Pharmacology/Toxicology | venetoclax | CYP3A interactions | rituximab | population pharmacokinetics | renal and hepatic impairment
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 65 - 75
Journal Article
Journal Article
HAEMATOLOGICA, ISSN 0390-6078, 10/2019, Volume 104, Issue 11, pp. 2258 - 2264
T he utility of positron emission tomography-computed tomography (PET-CT) in distinguishing Richter's transformation versus chronic lymphocytic leukemia (CLL)... 
TRANSFORMATION | 17P DELETION | GM-CSF | CYCLOPHOSPHAMIDE | VENETOCLAX | RITUXIMAB | IBRUTINIB | OPEN-LABEL | HEMATOLOGY | FLUDARABINE | RICHTER-SYNDROME
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 4395 - 4395
Abstract Background: Venetoclax (VEN) is a potent, highly selective, orally bioavailable small-molecular BCL2 inhibitor that is FDA-approved for patients (pts)... 
Journal Article
Journal Article
Journal Article